In May 2026, the company reported positive Phase II/III trial results for its investigational next-gen immune drug TAK-881 (immune globulin subcutaneous (human), 20% solution (SCIG 20%) with recombinant human hyaluronidase), which showed comparable efficacy, safety and immune protection to its existing lower dose immune globulin therapy HyQvia (immune globulin infusion (human) 10% with recombinant human hyaluronidase) in primary immunodeficiency disease, while offering the potential for lower infusion volumes and shorter treatment times.
It's a different tool entirely, one that works upstream in the brain rather than downstream in the blood vessels, and for a specific subset of patients, it solves a problem that no PDE-5 inhibitor can touch
Instead of being labeled high risk, they look like someone actively stabilizing and improving
Chemical & Peptide Information Important Notice: TB-500 supplied in this blend refers specifically to full-length Thymosin Beta-4 and is chemically distinct from TB-500 fragment variants (e.g., Frag 1723) offered by some suppliers
Age obviously this isnt one you can avoid
Skeletal muscle-specific overexpression of uncoupling protein 3 (UCP-3, an inner mitochondrial membrane transporter that dissipates mitochondrial proton gradients) protected against HFD-induced insulin resistance in skeletal muscle, enhanced energy expenditure, and reduced PKC activity and membrane-associated DAG levels [172]
